Nurix Therapeutics (NASDAQ:NRIX – Free Report) had its price target lowered by Wells Fargo & Company from $23.00 to $20.00 in a research note published on Friday, Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock. A number of other research firms also recently weighed in on NRIX. Needham & […]
Data reveal oncogenic scaffold function of BTK mutations that lack kinase activity and show these mutations remain susceptible to degradation by NX-2127 .
Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have earned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued a report on […]
Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been assigned an average recommendation of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have updated their coverage on the […]